This new 18-country report is available by country, market segment, section, or individual test.
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures; compares features of major analyzers; profiles leading market players and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
The report explores business and technological trends; provides test volume and sales forecasts for 40 hemostasis procedures; compares features of major analyzers; profiles leading market players and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Rationale
The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromogenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, IT and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.Country Analyses
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, VietnamCompetitive Assessments
- Extensive strategic profiles of major suppliers and emerging market entrants.
Current and Emerging Products
- Review of established and emerging procedures.
- Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.
Technology Review
- Analysis of current and emerging technologies and their potential market applications.
- Companies developing or marketing new technologies and products by test.
Strategic Recommendations
- Product development and business expansion opportunities with significant market appeal.
- Ideal product models with tentative prices and operating characteristics.
- Alternative market penetration strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.
